Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27400932 | 0.89 | OPRM1 (0.33) | OPRM1 | |
| SCHEMBL10119957 | 0.88 | HRH3 (0.34) | OPRM1 | |
| SCHEMBL20756869 | 0.87 | KDM2B (0.33) | KDM2B | |
| SCHEMBL24844831 | 0.84 | KDM2B (0.39) | KDM2B | |
| SCHEMBL10119953 | 0.83 | MAP3K12 (0.30) | — | |
| SCHEMBL20756780 | 0.82 | OPRM1 (0.35) | OPRM1 | |
| SCHEMBL26000758 | 0.79 | OPRM1 (0.33) | OPRM1 | |
| SCHEMBL16075167 | 0.78 | HTR3A (0.33) | OPRM1KDM2B | |
| SCHEMBL14754867 | 0.77 | OPRM1 (0.32) | OPRM1KDM2B | |
| SCHEMBL27423217 | 0.77 | TLR9 (0.34) | OPRM1KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190298724-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| US-10376513-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190134040-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-9730939-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730939-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9707233-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707233-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-20190134040-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-20190298724-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-10376513-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | OPRM1 2583/4885KDM2B 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.